Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03149055 · ClinicalTrials.gov registry record · Phase 2
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT03149055: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03149055 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 99 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03149055, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of this study is to study the effects of isavuconazole in preventing fungal infections in patients who have had a hematopoietic stem cell transplant (HCT).
Interventions
- DRUG Isavuconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2017-05-04 |
| Est. Completion | 2021-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03149055
The ClinicalTrials.gov registry entry for NCT03149055 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Isavuconazole is the first listed.
NCT03149055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03149055 about?
NCT03149055 is a clinical study titled "Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)". The purpose of this study is to study the effects of isavuconazole in preventing fungal infections in patients who have had a hematopoietic stem cell transplant (HCT).
What is the current status of trial NCT03149055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2017-05-04. Estimated completion is 2021-11-08.
What interventions are being tested in trial NCT03149055?
The interventions under investigation include: Isavuconazole (DRUG).
Who is sponsoring clinical trial NCT03149055?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.